GlassScriptPhysician profile
Maria C Basanez
NPI 1972109155
$9,049.40
in general payments reported to CMS, 2019-2025
21 companies · $2,793 in 2025
The $2,793 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.28 · 2022: $1,441 · 2023: $2,325 · 2024: $2,455 · 2025: $2,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,572.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,320.38 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,212.09 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $931.89 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $857.64 | 2022-2025 | |
| Alkermes, INC. | $711.82 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $612.28 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $570.58 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $568.60 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $526.99 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $418.39 | 2025 | Cobenfy |
| Lundbeck LLC | $395.18 | 2024-2025 | Rexulti |
| Indivior INC. | $296.39 | 2022-2024 | Perseris |
| Bausch Health US, LLC | $214.50 | 2022-2025 | Aplenzin |
| Almatica Pharma LLC | $142.77 | 2023-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $97.16 | 2022-2024 | Ingrezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $76.13 | 2025 | Erzofri Extended-Release |
| Merck Sharp & Dohme LLC | $26.86 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $18.68 | 2024 | Xelstrym, Secuado |
| Acadia Pharmaceuticals INC | $18.45 | 2023 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $17.76 | 2022 | |
| Penumbra, INC. | $14.86 | 2023 | Penumbra System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Basanez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.